IRIS - Res&Arch Institutional Research Information System - Research & Archive

BOLLI, Geremia Brunetto
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.655
EU - Europa 5.837
AS - Asia 4.725
SA - Sud America 838
AF - Africa 127
OC - Oceania 21
Continente sconosciuto - Info sul continente non disponibili 9
Totale 18.212
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.525
SG - Singapore 2.289
UA - Ucraina 1.091
IE - Irlanda 836
RU - Federazione Russa 823
SE - Svezia 749
CN - Cina 655
BR - Brasile 648
IT - Italia 643
HK - Hong Kong 514
FR - Francia 441
VN - Vietnam 407
DE - Germania 403
FI - Finlandia 321
GB - Regno Unito 193
TR - Turchia 161
KR - Corea 138
BD - Bangladesh 132
IN - India 98
AR - Argentina 68
ES - Italia 65
AT - Austria 54
CA - Canada 54
PL - Polonia 53
MX - Messico 48
ZA - Sudafrica 48
JP - Giappone 43
IQ - Iraq 41
NL - Olanda 34
UZ - Uzbekistan 33
PK - Pakistan 32
CH - Svizzera 30
CO - Colombia 27
ID - Indonesia 25
PH - Filippine 25
SA - Arabia Saudita 25
EC - Ecuador 24
CZ - Repubblica Ceca 22
MA - Marocco 22
AU - Australia 19
PE - Perù 19
BE - Belgio 16
PY - Paraguay 14
VE - Venezuela 14
AZ - Azerbaigian 13
KE - Kenya 13
MY - Malesia 12
CL - Cile 10
GR - Grecia 10
JO - Giordania 10
LB - Libano 10
JM - Giamaica 9
LT - Lituania 9
TN - Tunisia 9
AE - Emirati Arabi Uniti 8
DZ - Algeria 8
EG - Egitto 8
NP - Nepal 8
RO - Romania 8
BO - Bolivia 7
OM - Oman 7
RS - Serbia 6
TH - Thailandia 6
EU - Europa 5
IL - Israele 5
PS - Palestinian Territory 5
UY - Uruguay 5
AL - Albania 4
DK - Danimarca 4
ET - Etiopia 4
KG - Kirghizistan 4
KZ - Kazakistan 4
TT - Trinidad e Tobago 4
BA - Bosnia-Erzegovina 3
CR - Costa Rica 3
EE - Estonia 3
GE - Georgia 3
HU - Ungheria 3
PA - Panama 3
TW - Taiwan 3
XK - ???statistics.table.value.countryCode.XK??? 3
AO - Angola 2
BB - Barbados 2
BG - Bulgaria 2
BH - Bahrain 2
BW - Botswana 2
BY - Bielorussia 2
CI - Costa d'Avorio 2
KW - Kuwait 2
NZ - Nuova Zelanda 2
SI - Slovenia 2
SN - Senegal 2
ZW - Zimbabwe 2
DO - Repubblica Dominicana 1
GD - Grenada 1
GF - Guiana Francese 1
GT - Guatemala 1
HN - Honduras 1
HR - Croazia 1
HT - Haiti 1
Totale 18.192
Salva come PNG Salva come JPEG
Città #
Singapore 1.551
Dublin 836
Chandler 772
San Jose 644
Jacksonville 582
San Mateo 537
Hong Kong 512
Ashburn 333
Boardman 333
Santa Clara 276
Moscow 252
Medford 248
Princeton 246
Lauterbourg 214
Altamura 206
Dong Ket 192
Wilmington 184
Lawrence 146
Seoul 137
Beijing 124
Andover 120
Izmir 112
Perugia 111
New York 110
Munich 105
Ann Arbor 104
Des Moines 104
Los Angeles 94
Saint Petersburg 78
Ho Chi Minh City 77
Helsinki 74
The Dalles 62
Piscataway 55
São Paulo 54
Valencia 49
Rome 44
Norwalk 43
Hanoi 42
Frankfurt am Main 41
Tokyo 36
Woodbridge 36
Brooklyn 35
Chicago 33
Shanghai 31
Turku 29
Warsaw 29
Falls Church 24
Fremont 24
Nuremberg 24
Milan 23
Orem 23
Belo Horizonte 22
Dallas 22
Tashkent 22
Vienna 19
Amsterdam 18
Amelia 17
Stockholm 17
San Paolo di Civitate 16
Brussels 15
Da Nang 15
Denver 15
San Francisco 15
Baghdad 14
Bologna 14
Changsha 14
Istanbul 14
London 14
Rio de Janeiro 14
Ankara 13
Atlanta 13
Johannesburg 13
Montreal 13
Poplar 13
Porto Alegre 13
Falkenstein 12
Baku 11
Boston 11
Brno 11
Campinas 11
Houston 11
Manchester 11
Mumbai 11
Riyadh 11
Tianjin 11
Toronto 11
Auburn Hills 10
Bexley 10
Casablanca 10
Guayaquil 10
Lima 10
Phoenix 10
Amman 9
Brasília 9
Chennai 9
Den Haag 9
Foligno 9
Goiânia 9
Guangzhou 9
Haiphong 9
Totale 10.780
Salva come PNG Salva come JPEG
Nome #
Ipoglicemia da iperinsulinismo organico: un caso di nesidioblastosi dell’adulto. 215
Adrenaline vs glucagon in the primacy of glucose counterregulation 173
Different brain responses to hypoglycemia induced by equipotent doses of long-acting insulin analog detemir and human regular insulin in humans 157
Hypoglycemia 151
Administration of neutral protamine Hagerdon insulin at bedtime versus with dinner in type 1 diabetes mellitus to avoid nocturnal hypoglycemia and improve control. A randomized, controlled trial. 150
Acute, short-term hyperglycemia enhances shear stress-induced platelet activation in patients with type II diabetes mellitus. 147
Basal-bolus insulin therapy in Type 1 diabetes: comparative study of pre-meal administration of a fixed mixture of insulin lispro (50%) and neutral protamine lispro (50%) with human soluble insulin. 141
18. Insulin required for prandial ghrelin suppression in humans 136
Effect of the amino acid alanine on glucagon secretion in non-diabetic and type 1 diabetic subjects during hyperinsulinaemic euglycaemia, hypoglycaemia and post-hypoglycaemic hyperglycaemia. 134
[Behavior of plasma androgens in cases of adrenal pathology]. 132
A reliable and reproducible test for adequate glucose counterregulation in type I diabetes mellitus. 127
Alternative routes of insulin delivery 126
Portal vein glucose sensors do not play a major role in modulating physiological responses to insulin-induced hypoglycemia in humans. 126
Abnormal glucose counterregulation in insulin-dependent diabetes mellitus. Interaction of anti-insulin antibodies and impaired glucagon and epinephrine secretion. 126
A novel surrogate index for hepatic insulin resistance. 124
Adrenergic activity and glycometabolic compensation in patients with diabetes mellitus]. 123
Circulating palmitoleic acid is an independent determinant of insulin sensitivity, beta cell function and glucose tolerance in non-diabetic individuals: a longitudinal analysis 123
Aspetti attuali del Diabete Mellito 2002 120
Pharmacokinetics and pharmacodynamic of therapeutic dose of basel insulins NPH, Glargine and Detemir after one week of daily administration at bedtime in Type 2 daibates: a randomized, cross-over study. 119
Counterregulatory hormone and symptom responses to insulin-induced hypoglycemia in the postprandial state in humans 119
Comparison of pharmacokinetics and-dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes mellitus: a double-blind, randomized, cross-over study. 118
Differential Effects of Adiposity on Pharmacodynamics of Basal Insulins NPH, Glargine, and Detemir in Type 2 Diabetes mellitus. 116
Prevention of hypoglycemia while achieving good glycemic control in type 1 diabetes: the role of insulin analogs 115
Autoantibody recognition of COOH-terminal epitopes of GAD65 marks the risk for insulin requirement in adult-onset diabetes mellitus 113
Adrenergic mechanisms do not contribute to glucose counterregulation during acute insulin-induced hypoglycaemia in normal man. 113
Ipoglicemia: implicazioni cliniche e impatto sulla salute 112
Contribution of amino acids and insulin to protein anabolism during meal absorption. 111
Short-term effects of the long-acting insulin analog detemir and human insulin on plasma levels of insulin-like growth factor-I and its binding proteins in humans. 111
Uso dell’analogo ad azione rapida lispro con l’analogo ad azione ritardo glargine nel trattamento intensivo del T1DM 110
Adrenergic mechanisms contribute to the late phase of hypoglycemic glucose counterregulation in humans by stimulating lipolysis. 110
Anti-hyperglycaemic mechanisms of benfluorex in type II diabetes mellitus 109
Influence of the ACE gene insertion/deletion polymorphism on insulin sensitivity and impaired glucose tolerance in healthy subjects. 107
Body weight, not insulin sensitivity or secretion, may predict spontaneous weight changes in nondiabetic and prediabetic subjects: the RISC study. 107
A direct comparison of long- and short-acting GLP-1 receptor agonists (taspoglutide once weekly and exenatide twice daily) on postprandial metabolism after 24 weeks of treatment. 107
Pharmacokinetics and pharmacodynamics of insulin glargine given in the evening as compared with in the morning in type 2 diabetes 107
Insulin is required for prandial ghrelin suppression in humans 107
[Effects of circulating anti-insulin antibodies on the kinetics of injected insulin in type I diabetes mellitus]. 105
Counterregulatory hormone and symptom responses to insulin-induced hypoglycaemia in the postprandial state in humans 103
Intensive insulin treatment in diabetic children 101
Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting analogue at mealtime. A three month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime. 101
Analysis of short-term changes in reversibly and irreversibly glycosylated haemoglobin A I: Relevance to diabetes mellitus 99
Nocturnal blood glucose control in type I diabetes mellitus. 99
Influence of Apolipoproteins on the Association Between Lipids and Insulin Sensitivity: A cross-sectional analysis of the RISC Study 99
Establishing the deficiency of glucagon response to hypoglycemia in humans 99
Insulin treatment and its complications 97
Treatment and prevention of hypoglycemia and its unawareness in Type 1 diabetes mellitus 96
Pivotal role of timely basal insulin replacement after metformin failure in sustaining long-term blood glucose control at a target in Type 2 diabetes. 96
The dawn phenomenon in type 1 (insulin-dependent) diabetes mellitus: magnitude, frequency, variability, and dependency on glucose counterregulation and insulin sensitivity 95
Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with Type 1 diabetes mellitus given meal-time lispro insulin 95
Hyperglycemia alters the physico-chemical properties of proteins in erythrocyte membranes of diabetic patients 94
Comparative pharmacodynamic and pharmacokinetic characteristics of subcutaneous insulin glulisine and insulin aspart prior to a standard meal in obese subjects with type 2 diabetes. 94
Hyperglycemia, Both Chronic and in Short-Term Peaks, Results in Rapid Increase of Expression of Monocyte Inducible Cyclooxygenase (COX-2) in Subjects with T2DM 94
Equipotency of insulin glargine 300 and 100 U/mL with intravenous dosing but differential bioavailability with subcutaneous dosing in dogs 94
Mechanisms of insulin resistance after insulin-induced hypoglycemia in humans: the role of lipolysis. 93
Glucagon: the effects of its excess and deficiency on insulin action 93
PHARMACOKINETIC AND PHARMACODYNAMIC HEAD-TO-HEAD COMPARISON OF CLINICAL, EQUIVALENT DOSES OF INSULIN GLARGINE 300 U/ML AND INSULIN DEGLUDEC 100 U/ML IN TYPE 1 DIABETES 93
Plasma sCD36 is associated with markers of atherosclerosis, insulin resistance and fatty liver in a nondiabetic healthy population. 93
Pharmacokinetics, pharmacodynamics, and modulation of hepatic glucose production with insulin glargine U300 and glargine U100 at steady state with individualized clinical doses in type 1 diabetes 92
Greater Suppression of Glucagon, Lipolysis, and Ketogenesis with Insulin Glargine U300 as Compared with Glargine U100 in Type 1 Diabetes Mellitus 92
Impiego dell’analogo dell’insulina glargine in una paziente affetta da diabete di tipo 2 con grave resistenza insulinica. 91
Intensive replacement of basal insulin in patients with Type 1 diabetes mellitus given rapid-acting insulin analogue at meal-time: a three-month comparison between administration of NPH four times daily and glargine insulin at dinner or bedtime. 91
A case of neoplastic hemorrhagic pericarditis. 90
Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (OpT2mise): a randomised open-label controlled trial 89
Il nuovo analogo dell’insulina ad azione ritardata glargine: caratteristiche ed uso terapeutico nel diabete mellito 89
Ghrelin is not necessary for adequate hormonal counterregulation of insulin-induced hypoglycemia 89
Successful use of insulin glargine during entire pregnancy until delivery in six Type 1 diabetic women. 89
Post-hypoglycaemic hyperketonaemia does not contribute to brain metabolism during insulin-induced hypoglycaemia in humans. 89
Metabolism of insulin glargine after repeated daily subcutaneous injections in subjects with type 2 diabetes. 89
Pharmacokinetics and pharmacodynamics of the long-acting insulin analog glargine after 1 week of use compared with its first administration in subjects with type 1 diabetes. 88
Chloroquine reduces whole body proteolysis in humans 88
Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro 88
Rational use of insulin analogues in the treatment of Type 1 diabetes mellitus 86
Effect of oral amino acids on counterregulatory responses and cognitive function during insulin-induced hypoglycemia in nondiabetic and type 1 diabetic people. 86
La resistenza insulinica nel diabete mellito di tipo I Effetti della terapia insulinica intensiva 86
Ricoveri per ipoglicemia grave in soggetti con diabete mellito di tipo 2: impatto clinico e costi sanitari 86
HYPERGLYCEMIA-INDUCED PLATELET ACTIVATION IN TYPE 2 DIABETES MELLITUS IS RESISTANT TO ASPIRIN BUT NOT TO A NITRIC OXIDE-DONATING AGENT. 85
Erythrocyte concentration of glycolytic phosphorylated intermediates and adenosine nucleotides in subjects with diabetes mellitus. 85
Efficacy and safety of lixisenatide once daily vs. placebo in people with Type 2 diabetes insufficiently controlled on metformin (GetGoal-F1). 84
Clinical strategies for controlling peaks and valleys: type 1 diabetes 83
COMPARISON OF VILDAGLIPTIN AND PIOGLITAZONE IN PATIENTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED WITH METFORMIN. 83
Superiority of insulin analogues versus human insulin in the treatment of diabetes mellitus. 83
L’ipoglicemia silente nella pratica clinica quotidiana: come diagnosticarla, gestirla e prevenirla 83
Insulin sensitivity and carotid intima-media thickness: relationship between insulin sensitivity and cardiovascular risk study. 82
Glargine metabolism over 24 h following its subcutaneous injection in patients with type 2 diabetes mellitus: A dose–response study 82
Evaluation of the accuracy of a microdialysis-based glucose sensor during insulin-induced hypoglycemia, its recovery, and post-hypoglycemic hyperglycemia in humans. 81
Pharmacokinetics and pharmacodynamics of NPH insulin in type 1 diabetes: The Importance of appropriate resuspension before subcutaneous injection 81
Insulin treatment in type 1 diabetes. 80
Glucose variability and complications. 80
Opinioni a confronto: quando e come usare il microinfusore rispetto alla terapia insulinica multi-iniettiva nella terapia intensiva del diabete mellito tipo 1. 80
Kinetic behaviour of the glucose-hemoglobin labile adduct in normal and diabetic erythrocytes. 80
Thirty years of research on the dawn phenomenon: lessons to optimize blood glucose control in diabetes. 80
Glucose variability and complications. 79
Insulins today and beyond 79
Effect of cigarette smoking and of a transdermal nicotine delivery system on glucoregulation in type 2 diabetes mellitus 79
Obesity and carotid artery remodeling 79
Fluctuation of serum basal insulin levels following single and multiple dosing of insulin glargine. 77
ROLE OF PANCREATIC BETA-CELL FUNCTION ON A-CELL RESPONSE TO HYPOGLYCEMIA IN MAN 77
Effect of storage temperature of insulin on pharmacokinetics and pharmacodynamics of insulin mixtures injected subcutaneously in subjects with type 1 (insulin-dependent) diabetes mellitus 75
Responses to hypoglycemia in diabetic autonomic neuropathy. 75
The effect of menopause on carotid artery remodelling, insulin sensitivity, and plasma adiponectin in healthy women. 74
Totale 10.179
Salva come PNG Salva come JPEG
Categoria #
all - tutte 86.647
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 86.647
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021238 0 0 0 0 0 0 0 0 0 0 0 238
2021/20221.843 42 332 46 130 52 16 10 642 18 52 210 293
2022/20232.836 259 486 38 201 204 346 6 117 1.064 7 85 23
2023/20241.090 72 122 50 19 15 10 208 24 101 52 216 201
2024/20252.731 19 313 58 132 424 53 59 230 690 173 322 258
2025/20266.081 460 347 344 721 784 456 1.138 311 766 476 155 123
Totale 18.623